The Biotechnology week, distilled.

Regulation and policy09 Sep

On September 9, 2026, the US FDA granted accelerated approval to AstraZeneca's drug Etcamah.

Regulation and policy09 Sep

The US Food and Drug Administration (FDA) announced that priority review voucher fees will decrease for the 2027 fiscal year.

Regulation and policydue 10 Sep 202609 Sep

The National Commission into the Regulation of AI in Healthcare, led by Professors Alastair Denniston and Henrietta Hughes, published its recommendations on 10 September 2026 to improve AI regulation in the UK.

Read at gov.uk ↗

Regulation and policy08 Sep

The US Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's drug camizestrant on September 8, 2026.

Regulation and policy07 Sep

The US Food and Drug Administration (FDA) is implementing stricter enforcement measures regarding clinical trial data originating from China and other foreign countries.

Regulation and policyreported 09 Sep03 Sep

On September 9, 2026, a U.K. commission released 44 recommendations for regulating artificial intelligence in medicine.

Read at statnews.com ↗

8 of 9 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.

What funding rounds and acquisitions happened in biotechnology this week?

The week’s notable investments, financing rounds, acquisitions and strategic deals.

8 of 15 events

Funding and M&A13 Sep

GE HealthCare is reportedly in advanced talks to acquire the radiopharmaceutical developer Sofie Biosciences.

Funding and M&A10 Sep

In August 2026, Chinese advanced molecular therapy firms continued to secure significant investment funding.

Read at commercialobserver.com ↗

Funding and M&Areported 11 Sep10 Sep

Multifamily developer LCOR acquired a life sciences development site at 309 East 94th Street in Manhattan's Upper East Side from Taconic Partners for $73 million.

Funding and M&A10 Sep

Frazier Life Sciences has successfully raised over $1.1 billion for its public fund dedicated to small and midsize biotech companies.

Funding and M&A09 Sep

Schrödinger has launched a new biotechnology company named Tectora Therapeutics, which will focus on immunology and inflammation research.

Funding and M&A09 Sep

Solstice Oncology has raised $225 million in a series A funding round.

Funding and M&A09 Sep

Luma Group announced the final close of its inaugural venture capital fund dedicated to life sciences.

Funding and M&A08 Sep

BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.

Read at fiercehealthcare.com ↗

8 of 15 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.

What products launched in biotechnology this week?

Notable product launches, releases and platform updates from the week.

5 events

Product launches11 Sep

The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.

Product launches10 Sep

Clinical research company nPhase launched an end-to-end clinical data management platform on September 10, 2026.

Product launches08 Sep

H1 is utilizing connected intelligence to enhance clinical development processes.

Read at deepmind.google ↗

Product launches08 Sep

On September 8, 2026, Google DeepMind launched AlphaGenome Atlas, a platform containing predictions for the molecular effects of 9 billion single-nucleotide variants in the human genome.

Product launches08 Sep

AstraZeneca's R&D chief Sharon Barr announced that the company has secured an FDA priority review for its IL-33 antibody treatment for chronic obstructive pulmonary disease (COPD).

What financial results were reported in biotechnology this week?

Earnings, guidance and other financial results reported this week.

1 event

Financial results11 Sep

Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.

Read at sciencedaily.com ↗

What research was published in biotechnology this week?

New research findings and studies published this week.

8 of 24 events

Research12 Sep

Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.

Research11 Sep

Researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London published a study in Nature Genetics on September 11, 2026, regarding the impact of cancer treatments on healthy tissue.

Research11 Sep

Disc Medicine presented Phase II clinical trial data for its investigational agent DISC-3405.

Research10 Sep

Researchers at the Salk Institute, led by Gerald Shadel, have identified a biological pathway where chronic exposure to interferon II (IFN-II) causes mitochondrial dysfunction, leading to immunosuppression in cancer.

Research10 Sep

Researchers at Cedars-Sinai Health Sciences University identified that the protein PD-L2 helps senescent cells evade the immune system, contributing to age-related dysfunction.

Research09 Sep

Cleveland Clinic, RIKEN, and IBM have been named finalists for the 2026 ACM Gordon Bell Prize for their quantum-HPC chemistry research.

Read at ibm.com ↗

Research09 Sep

Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.

Read at foxbusiness.com ↗

Researchreported 09 Sep08 Sep

Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.

Read at futurism.com ↗

8 of 24 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.

What incidents and outages hit biotechnology this week?

Incidents, outages and safety events reported this week.

2 events

Incidents and safety10 Sep

Anthropic reported on September 10, 2026, that it disrupted several attempts by researchers to use its Claude AI models for biological research potentially linked to biological weapons development.

Incidents and safetyreported 11 Sep10 Sep

Anthropic reported that it has disrupted multiple attempts to use its AI models, including Claude, for research related to biological weapons development over the past eight months.

Read at aljazeera.com ↗

What partnerships were announced in biotechnology this week?

Partnerships, integrations and joint projects announced this week.

2 events

Partnerships08 Sep

ProBioGen and Transgene have expanded their existing collaboration through a new license agreement for the AGE1.CR.pIX cell line.

Partnerships07 Sep

Carelon Research, led by President Mark Cziraky, has entered into a partnership with Manifold to enable researchers to analyze Carelon's real-world data alongside third-party datasets.

What people moved in and out of biotechnology roles this week?

Executive appointments and departures reported this week.

2 of 3 events

People moves10 Sep

In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.

Read at biospace.com ↗

People movesreported 09 Sep07 Sep

On September 7, 2026, the U.S. Department of Health and Human Services (HHS) announced four permanent senior leadership appointments at the FDA.

Read at foodnavigator.com ↗

2 of 3 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.

What else happened in biotechnology this week?

Developments from the week that fit none of the other sections.

8 of 9 events

Other developments11 Sep

Bebop is expanding its dairy-free, plant-fat ice cream brand from Taiwan into the broader APAC market.

Other developments11 Sep

Nacho Quinones and Aisling O'Loughlin discuss the implementation of Synthetic Advisory Boards (S-ABs) in the biopharmaceutical industry as of September 2026.